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Algorithms designed to precisely identify disease severity for a given patient within a managed care population 
are helpful in organizing targeted interventions. These algorithms are also attracting considerable attention within 
the medical research community. Several health risk screening instruments have been developed; however, these 
involve survey methodologies and have several shortcomings. We present a valid and efficient method for predicting 
healthcare resource utilization among asthmatics in an Health Maintenance Organization (HMO) population. 
First, various diagnosis, procedure and pharmacy billing codes were used to identify the asthmatics within the 
database. The screening algorithm awards points each time one of these codes is identified for an HMO member. By 
varying the number of points necessary to consider a patient asthmatic, the sensitivity, specificity, positive and 
negative predictive values of the algorithm can be adjusted. Once identified as asthmatic, subjects were then 
stratified into severity levels based on pharmacy data. Severity stratification was validated directly by measuring 
asthma-related bed days utilized during the 12 months following the date of stratification. Our identification 
algorithm estimated an asthma prevalence of 3.84% within the studied population, with age-specific prevalence 
estimates that closely mirrored previously published survey data. There was a monotonic relationship between 
pharmacy severity levels and inpatient resource utilization. For example, asthmatics in severity level 1 used only 92 
hospital days per 1000 asthmatics in the year following characterization, while those in levels 2-5 used 133, 156,277 
and 1168 hospital days (P<O.OOl), respectively. Results from this model can be used as adjusters in other predictive 
models or stand alone to represent a patient’s severity of illness. 
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Introduction and purpose 
As insurers continue to develop sophisticated disease 
management programs, their ability to identify and 
characterize patients with selected chronic diseases is 
attracting more attention within the medical research 
community. Identifying patients with a specific chronic 
disease is necessary to determine who is at risk for 
avoidable and often costly exacerbations. Further char- 
acterizing those with a disease helps to precisely identify the 
level of severity for a specific patient so that targeted 
interventions, consistent with an individual’s needs, can be 
provided. Together, identification and characterization of 
the population enables healthcare providers to efficiently 
expend healthcare education and other resources on those 
who may need them the most. 
Recently, several health risk screening instruments have 
been developed to better identify and characterize patients 
with chronic illnesses. Such instruments are usually 
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administered to insureds or providers via the mail or the 
telephone. However, these survey methodologies have 
several shortcomings. First, they are typically very expen- 
sive due to mail, telephone and personnel costs. Addition- 
ally, such methodologies often yield invalid and incomplete 
information. For example, response rates for traditional 
mail surveys under these circumstances are typically less 
than 20% (1). Furthermore, the validity of the information 
gained from those who do respond is suspect consequent to 
substantial respondent recall errors or intentional misre- 
presentation. 
Administrative claims and encounter data can be used to 
solve many of the efficiency and validity shortfalls 
associated with survey data. Administrative claims and 
encounter data are already available to insurers for billing 
and other purposes. Therefore, the costs associated with 
survey administration are avoided. Furthermore, such data 
sources are generally accurate representations of services 
provided to and received by individual insureds. Finally, 
these data are not dependent upon response rates or 
respondent recall. 
The purpose of this article is to present an improved valid 
and efficient methodology designed to identify and char- 
acterize patients with asthma within an HMO population. 
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We selected this disease since it is prevalent, chronic and 
potentially costly when inappropriately managed, and its 
course can be affected with appropriate disease manage- 
ment. The general methodology presented here can be 
applied to other chronic diseases as well. 
Methods 
DATA 
Data for this study were obtained from a large HMO with 
more than 2 million fully-insured members and operating in 
13 eastern states plus the District of Columbia. Specific 
data sources included pharmacy claims, specialist claims, 
inpatient claims, radiology claims, laboratory claims, 
primary care provider encounter information and admi- 
nistrative membership information. Each data source was 
linked to a patient-specific identification number to create 
one omnibus data source. 
All HMO members who met specific criteria suggesting 
the presence of asthma were eligible for the study. The 
sample used for the study was narrowed to include only 
those who were members for a minimum of 12 months 
starting in October 1994 and who had a pharmacy plan. 
These criteria ensured that individual members had enough 
history with the HMO to generate claims and encounter 
data, if appropriate. The resultant sample consisted of 
28 6 16 insured members. 
MEASUREMENT 
Table 1 presents the diagnosis, procedure and pharmacy 
billing codes that were used to identify asthmatics. Each 
code was widely accepted as asthma-specific or related. 
Programs were created to identify those who had any of the 
codes. Each time one of the codes represented in Table 1 
came up for an HMO member, the individual was awarded 
a point. With this methodology, the specificity, sensitivity, 
negative and positive predictive values of the screening 
algorithm could be adjusted contingent upon the number of 
points required to consider an individual an asthmatic (2). 
Since many of these codes could be present for non- 
asthmatics, specific selection criteria were incorporated. 
These criteria were decided upon as a result of a feedback 
process where the HMO would field lists of asthmatics to 
the primary care physician population. In turn, the primary 
care physicians would return information indicating which 
patients were falsely labeled as asthmatic and which were 
incorrectly left off the list. The results were then evaluated 
to identify what could be done to improve the identification 
codes and algorithms. In this way, the misclassification 
errors previously reported (3) could be minimized. While 
this method of algorithm validation suffers from physician 
non-response to the survey, we have no reason to believe 
that the responses were biased in any way. These surveys 
were used to guide the research team to those observations 
that warranted closer scrutiny to determine the potential 
cause for misclassification. Of course, those who were 
misidentified would probably be in the lowest severity 
TABLE 1. Administrative data selection criteria 
Inclusion Criteria 
Diagnosis ICD-9 Criteria 
493.00-493.99 Asthma conditions 
Procedure CPT-4 Criteria 
WO200 Asthma control program* 
WOlOO Asthma control program* 
94795 Asthma control program” 
99108 Special home-care asthma program” 
80198 TheophylIine** 
84420 Theophylline, blood or saliva** 
Pharmacy NDC Criteria** 
Anti-inflammatory asthma agents 
Asthma combinations 
Steroid inhalants 
Sympathomimetics 
Xanthines 
Anticholinergics 
“Aetna U.S. Healthcare internal codes 
**sufficient if met on more that one claim at least 30 days 
apart in the age group O-44 years and no diagnosis criteria 
for chronic obstructive pulmonary disease 
category resulting in no impact on the application of the 
severity adjustment addressed here. 
The following selection criteria were used to increase the 
positive predictive value of our identification logic. First, an 
individual had to have at least three points from any 
database or have two points represented in at least two 
databases (i.e. pharmacy, laboratory, claims and/or en- 
counters) to be considered asthmatic. Since we were seeking 
to identify patients with chronic asthma, more than a single 
episode of wheezing was required. Additionally, if a patient 
was awarded all of his or her points from the pharmacy 
data, these points had to occur within a 12-month period. 
These requirements limited the number of false positives 
yielded from pharmacy data, given that some of the 
medications used for asthma may be used for other 
ailments. Finally, the evaluation of theophylline levels 
and the medications listed in Table 1 are used for chronic 
obstructive pulmonary disease (COPD) as well as for 
asthma. To further increase the positive predictive value of 
the identification algorithm and to avoid falsely concluding 
that an individual with COPD had asthma, all points 
derived from pharmacy and laboratory databases were 
voided for individuals who were older than 44 years of age 
or diagnosed with COPD. 
STRATIFICATION 
Patients who were identified as asthmatic were then 
stratified into pharmaceutically driven severity groups. 
Clinical definitions of severity, based on medication class 
requirements, have been previously published (4,5) but fail 
to account for differences in the amount of medication 
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used. The concept of mild, moderate and severe asthma was 
further developed into five ordinal pharmacy severity levels. 
The specific pharmaceutical criteria were determined based 
on a series of focus group interactions and collaboration 
with the National Heart, Lung and Blood Institute’s Asthma 
Clinical Research Network, and researchers from the HMO. 
Level 1: <3/I-agonists dispensed alone per year 
Level 2: >4P-agonists dispensed alone per year 
Level 3: Other asthma medications (not oral steroids) +/- 
P-agonists 
Level 4: Systemic steroids but not eligible for level 5 
Level 5: (At least 1 dose of systemic steroids for > 28 days 
or 23 doses of systemic steroids for any duration) and 24 
inhaled P-agonist dispenses per year plus other asthma 
medications. 
Individuals in the first two severity levels are considered 
mild asthmatics since they were dispensed /?-agonists alone. 
Since their asthma is being controlled only with P-agonists, 
these individuals are not likely to have significant disease. 
However, given the nature of the current clinical guidelines 
(4,5), asthmatics who require P-agonist inhalations more 
than once daily should be considered poorly controlled and 
should be placed on inhaled corticosteroids (ICS). There- 
fore, the mild asthmatics were separated into two groups to 
investigate whether or not those who required three or fewer 
j-agonist prescriptions per year would utilize fewer hospital 
resources than those requiring four or more. 
Those who required other asthma medications, such as 
xanthines, chromolyn, or anti-cholinergics but not inhaled 
steroids (ICS) were classified in the third severity category. 
In this group, the risk of an exacerbation is probably higher 
because the use of ICS is generally reserved for patients 
who experience persistent symptoms despite p-agonists. In 
addition, none of the other medications (except ICS) are 
generally considered as useful in relieving symptoms or 
aborting exacerbation as the P-agonists, so their presence 
may imply a higher risk for resource utilization. Of course, 
this group also includes the occasional patient who cannot 
tolerate b-agonists, or who may have technical difficulty 
with inhaler use. Regardless of the reason for their 
inclusion, the presence of other asthma medications is 
likely to signal more serious disease. 
Initiation of oral steroids defines a severely ill asthmatic 
(4,5). Asthmatics who were dispensed oral steroids were 
placed in the highest severity levels. By similar logic, this 
group was further broken into two groups. The fourth level 
included those who were dispensed fewer overall asthma- 
specific medications when compared to those in the fifth 
severity level. Using the amount of systemic steroid 
therapy, in combination with the amount of P-agonist 
dispensed, to define the most severe categories was done in 
order to minimize confounding by the multiple other 
conditions treated with steroids. 
VALIDATION 
Validation of the asthmatic identification model algorithm 
was accomplished primarily through the use of prevalence 
rate comparisons with other research. Here the prevalence 
rates were stratified by age to allow for comparisons with 
1987 National Health Interview data (6) and research 
conducted by Dodge and Burrows (7). These works were 
chosen as references because of their widespread clinical 
acceptance. The census data is generally accepted as 
reflective of the overall prevalence rates in the U.S.A. 
population, and the Dodge and Burrows data are believed 
to accurately represent age stratified prevalence rates. 
Severity characterization was validated directly by 
measuring the asthma-related bed days per thousand for 
each severity level, during the 12 months following the 
period when asthmatics were assigned severity levels. Our u 
priori expectations are that those in higher severity 
categories will use more bed days per thousand than those 
in lower severity categories if the pharmaceutically driven 
severity levels are accurate characterizations of the asth- 
matic populations’ risk of exacerbation. We selected 
asthma-related bed days per thousand consequent to the 
increased accuracy of inpatient diagnosis data provided in 
the HMOs claims system. Only those admissions containing 
asthma-related primary diagnoses were included in the bed 
day counts. 
Results 
The overall prevalence of asthma in the study population 
was estimated to be 3.84%. This result correlated well with 
the results from the 1987 National Health Interview 
statistics suggesting an overall 4% asthma prevalence rate. 
Age stratified comparisons also suggest very close agree- 
ment between the National Health Insurance Survey 
(NHIS) prevalence rates (i.e. 0.053 for those below 18 
years, 0,035 for those 18 to 44 years and 0.038 for those 
greater than 44 years) and those of this methodology (i.e. 
0.066, 0.031 and 0.01, respectively). Compared with the 
Dodge and Burrows’ data, the age-specific prevalence rates 
show more variation (see Fig. 1). The HMO data suggests a 
noticeably higher prevalence rate in the lowest age group. 
The lower prevalence rate presented in the HMO data for 
older age groups is likely to be a function of the positive 
predictive value enhancing criteria introduced to avoid 
misclassification with COPD. 
Figure 2 displays the percentage of asthmatics who fell 
within each of the five severity levels. Forty-nine percent of 
the asthmatics are in the lowest two severity levels, 
requiring only P-agonists for control. Twentji-four percent 
of the population fell into pharmacy severity level 3 and 
27% were in severity levels four and five combined. 
Our expectations were that those in the highest severity 
levels would be the most likely to have an acute 
exacerbation necessitating hospital admission. As expected, 
there was a monotonic relationship between patient severity 
level and the number of asthma-related bed days per 
thousand (Fig. 3). Only 92 hospital days per 1000 patients 
per year were utilized by those asthmatics in level 1. Level 2 
asthmatics required 133 days per 1000 patients annually. 
Asthmatics classified as moderate (level 3) utilized 156 
hospital bed days per 1000 patients per year. Of severe 
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FIG. 1. Prevalence comparisons study population vs. published data. q :, Natural; q : Health Maintenance Organization. 
asthmatics, level 4 patients required 277 days, and level 5 
patients utilized 1168 hospital bed days per 1000 patients 
per year. 
To test if there was a statistically significant difference in 
the number of asthma-specific inpatient days among the 
different severity levels, several statistics were calculated. 
First, an analysis of variance was calculated yielding an 
overall P-value of less than 0.001, therefore, rejecting the 
null hypothesis that the mean hospital days of the different 
severity level groups are equal (see Table 2). Second, four a 
priori hypotheses were tested to determine which, if any, of 
the severity levels yielded a significantly different average 
number of asthma-specific bed days when compared to its 
adjacent severity levels. Hence, the average days per 
thousand for severity level 1 was compared with severity 
level 2, severity level 2 was compared with severity level 3, 
level 3 was compared with 4, and 4 was compared with 5. 
The results of these comparisons were mixed (see Table 3). 
Severity level 1 was not significantly different from 2 and 
severity level 2 was not significantly different from 3. 
However, severity level 3 was significantly different from 4 
(P<O.OOl), and 4 was significantly different from 5 
(P<O.OOl).’ 
r These results reflect four a priori contrast two-tailed t-tests. The 
results were later confirmed with post hoc tests using the Tukey 
HSD and Scheffe multiple comparison tests controlling for 
experiment wise error rates. Note that the results of these post 
hoc comparisons confirmed the results of the n-puiovi hypotheses 
contrasts reflecting that the differences between groups three, four, 
and five were statistically significant. 
Level 5 
4% 
Level 1 
43% 
Level 2 
6% 
FIG. 2. Distribution of asthmatics by pharmacy severity 
level. 
Discussion 
We have shown how administrative claims and encounter 
data could be used to quickly and efficiently identify, and 
characterize into severity levels, patients with chronic 
disease. When applied appropriately, this methodology 
could be a very powerful tool. It may be most useful in 
targeting specific sub-populations for intensive intervention 
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FIG. 3. Asthma-related acute bed days per 1000 
asthmatics. 
programs that are consistent with their health needs. 
Furthermore, rapid identification of individuals at the 
highest risk for hospital bed utilization, and the targeting of 
appropriate programs to them, can help providers plan 
cost-effective resource allocation. 
Our study is somewhat limited by the relative inability to 
accurately estimate the identification algorithm’s specificity 
and sensitivity to the identification measure. Consequent to 
the limited nature of claims data, we could only conduct an 
indirect validation by comparing our administrative data 
derived prevalence rates with those of previous research. 
We believe that the general logic behind the identification 
algorithm is sound, and that its greatest utility is in identifying 
severely ill asthmatics at highest risk of significant morbidity. 
Based on the comparisons with other published asthma 
prevalence rates, our estimates appear to yield higher 
estimates in the younger population and lower estimates in 
the older population. The relatively high results could be 
the result of the inclusion of selected medications that are 
used for conditions other than asthma in the pediatric 
population. We expect that most of our false positives were 
in severity strata one and two. Our lower estimates are 
probably the result of our exclusion criteria for those over 
the age of 44 and those who had a diagnosis of COPD. 
Without additional primary data collection, it is not 
possible to determine whether or not previous studies 
yielded over-estimates or whether our estimates are too low. 
The results from this severity stratification can be used as 
inputs into more thorough models that take other risk 
factors into account. Age, gender and socio-economic 
status have been linked to the severity of several chronic 
diseases. Additional research is needed to identify these 
factors’ joint ability to identify high-risk individuals. 
Because sufficient information must be available for 
extended periods in order to identify and stratify individual 
patients, this methodology may only be appropriate for 
those with chronic diseases. Since acute illnesses have a 
rapid onset, such administratively driven identification and 
stratification methodologies may yield less useful results. As 
information systems become more sophisticated and data 
are collected in a more timely manner, acute care severity 
stratification can be developed such that clinicians could 
obtain severity information about their practice popula- 
tions in real time. Application of this severity stratification 
methodology to other diseases could be used as predictors 
in other statistical adjustment models or stand alone to 
represent a patient’s severity of illness. 
Additional research must be conducted to help refine 
interventions that have an impact on resource utilization 
and the health status of those in higher severity groups. 
Since those in higher severity groups are already receiving 
medications designed for high-risk patients, new non- 
pharmaceutical interventions must continue to be further 
explored and tested to determine their impact. Indeed, it is 
likely that primary care physicians have already identified 
many high-risk patients. As such, payers, employers and 
managed care companies must determine the best ways to 
help providers better care for this population. More 
research is necessary to determine what mix of patient 
education, patient counseling, disease management, home 
health care, primary care physician education, specialist 
care and other services would yield optimal health results 
for specific populations. 
TABLE 2. Analysis of variance testing the equality of mean bed days among the five severity levels 
Sum of squares Degrees of freedom Mean square F Significance 
Between 1214 4 303.5 88 <O~OOl 
Within 98 099 28 611 3.4 
Total 99 313 28615 
TABLE 3. Bivariate comparisons of number of bed days between adjacent severity levels 
Severity Levels compared l-statistic Degrees of freedom 2 tailed significance 
Level one and level two 0.852 28611 0.394 
Level two and level three 0.45 1 28611 0.652 
Level three and level four 3.159 28611 <O.OOl 
Level four and level five 14.632 28611 <O.OOl 
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